Compare Novavax Inc (NVAX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Phillips 66 — how do they compare? Novavax Inc trades at $9.86 (market cap $1.62B), while Phillips 66 trades at $262.99 (market cap $104.06B). The key difference: Phillips 66 is far larger — about 64.2× Novavax Inc's market cap, and Phillips 66 pays a 1.95% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PSX | |
|---|---|---|
Market Cap | $1.62B | $104.06B |
Sector | Health | Energy |
52-Week High | $11.19 | $260.78 |
52-Week Low | $6.22 | $126.76 |
Enterprise Value | $1.20B | $120.52B |
Dividend Yield | — | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Phillips 66 (PSX) trades at $259.14, up 1.59% over 24 hours and near its 52-week high, with bullish technical indicators and strong support at $258. The stock shows robust fundamentals, including a P/E of 14.79 and ROE of 24.02%, while recent quarterly earnings consistently beat expectations. Positive news highlights refining strength amid elevated energy prices, with institutional buying supporting momentum.
Outlook remains favorable due to earnings growth and cost initiatives, but risks include volatile refining margins and debt levels. Analysts are bullish with a $242.45 consensus target, though current price exceeds it, suggesting cautious optimism for further upside if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
